In an advanced melanoma trial, the major pathologic response to neoadjuvant pembrolizumab surpasses 50%.

Published Date: 25 Oct 2023

More than half of surgical specimens removed from patients with stage III–IV resectable melanoma showed a significant pathologic response, according to exploratory analyses of trial results.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot